FindTrial
Sign In

TO establish a relationship between mNutric Score and Quadricep Femoris Muscle Thickness in a critically ill patients

Relationship between modified Nutrition Risk in the Critically Ill (mNUTRIC) Score with quadriceps femoris muscle thickness in critically ill patients: A prospective observational study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/08/057046
Enrollment
96
Registered
2023-08-29
Start date
Unknown
Completion date
Unknown
Last updated
2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

None listed

Sponsors

SHRI BALAJI INSTITUTE OF MEDICAL SCIENCE
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: The patients aged between 18 year and 65 year . The patient’s family with readiness to include the patient in the research.

Exclusion criteria

Exclusion criteria: •Patients with deformities, lesions, fractures, and amputations of the lower extremities. •Patients with neuromuscular disease or critical illness neuropathy, •Patients with a history of chronic kidney disease, •Patients with a history of previous liver disease (cirrhosis of the liver, acute liver failure, or hepatoma) •Palliative patients.

Design outcomes

Primary

MeasureTime frame
The subject will be grouped into high-risk (5-9) and low-risk (0-4) patients based on the modified NUTRIC Score during ICU admission.The quadriceps femoris muscle thickness (QMLT) will be measured by ultrasonography on the 1st, 3rd, 5th, and 7th day of ICU treatment and every 3rd day thereafter till patient discharge from ICU or death. Primary Outcome aim to Establish a relationship between mNUTRIC Score and Quadriceps Femoris Muscle Thickness.Timepoint: one year—

Secondary

MeasureTime frame
• Relation between disease severity in terms of APACHE II and the SOFA score with the percentage muscle loss. • Relationship between calorie debt and muscle changes. • 28 days mortality benefit of intravenous protein therapy. Timepoint: on day 0,1,3,7,14,28days—

Countries

India

Contacts

Public ContactPANKAJ KUMAR

SHRI BALAJI INSTITUTE OF MEDICAL SCIENCE

prafullaagnihotri@gmail.com9685699030

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026